Logan Capital Management Inc. Decreases Stock Holdings in Becton, Dickinson and Company $BDX

Logan Capital Management Inc. lowered its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 9.8% during the second quarter, Holdings Channel reports. The institutional investor owned 1,444 shares of the medical instruments supplier’s stock after selling 156 shares during the period. Logan Capital Management Inc.’s holdings in Becton, Dickinson and Company were worth $249,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Saudi Central Bank acquired a new position in Becton, Dickinson and Company during the first quarter worth about $26,000. Smallwood Wealth Investment Management LLC acquired a new position in Becton, Dickinson and Company during the first quarter worth about $27,000. Cornerstone Planning Group LLC raised its position in Becton, Dickinson and Company by 341.4% during the first quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier’s stock worth $29,000 after acquiring an additional 99 shares during the last quarter. Kelly Lawrence W & Associates Inc. CA acquired a new position in Becton, Dickinson and Company during the first quarter worth about $31,000. Finally, WPG Advisers LLC acquired a new position in Becton, Dickinson and Company during the first quarter worth about $36,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Performance

Shares of BDX stock opened at $184.35 on Wednesday. Becton, Dickinson and Company has a one year low of $163.33 and a one year high of $251.99. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10. The company has a 50 day moving average price of $189.49 and a 200 day moving average price of $183.53. The firm has a market capitalization of $52.84 billion, a price-to-earnings ratio of 33.16, a price-to-earnings-growth ratio of 1.46 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 EPS for the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The firm had revenue of $5.32 billion during the quarter. Sell-side analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, Director Claire Fraser sold 917 shares of the business’s stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total transaction of $171,937.50. Following the completion of the sale, the director directly owned 22,226 shares in the company, valued at $4,167,375. The trade was a 3.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold 1,895 shares of company stock worth $358,995 in the last ninety days. 0.36% of the stock is owned by insiders.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. Wall Street Zen upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Wells Fargo & Company boosted their price objective on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a research report on Friday, August 8th. Morgan Stanley boosted their price objective on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a research report on Monday, August 11th. Weiss Ratings reissued a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research report on Wednesday, October 8th. Finally, Argus boosted their price objective on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research report on Monday, September 15th. Three investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat.com, Becton, Dickinson and Company has a consensus rating of “Hold” and a consensus price target of $205.40.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.